

AMENDMENTS TO THE CLAIMS

1-10. **Canceled**

11. **(Currently Amended)** A method for preventing surgical adhesions of tissue which comprises applying to tissue involved in surgery a biomaterial comprised of at least one auto-crosslinked derivative of an hyaluronic acid with an average molecular weight of 150,000 to 730,000 Daltons, wherein 4.5 to 5% of the carboxyl group of hyaluronic acid are cross-linked to the hydroxyl group of the same or different hyaluronic acid molecule, wherein said cross-linked derivative has a viscosity of at least 200 Pa*sec⁻¹ ~~to 450 Pa*sec⁻¹~~.

12. **Canceled**

13. **Canceled**

14. **Canceled**

15. **Canceled**

16. **(Previously Presented)** The method according to claim 11, wherein said viscosity is at least 250 Pa*sec⁻¹.

17. **(Currently Amended)** The method according to claim 11, 27 or 29, wherein said biomaterial further comprises a non-biodegradable synthetic polymer.

18. **(Previously Presented)** The method according to claim 17, wherein said synthetic polymer is at least one member selected from the group consisting of polypropylene, polyethylene, polyester and polytetrafluoroethylene.
19. **(Currently Amended)** The method according to claim 11, 27 or 29, wherein said biomaterial is in the form of a gel, a membrane, a mesh or a woven or non-woven tissue.
20. **(Currently Amended)** The method according to claim 11, 27 or 29, wherein said biomaterial further comprises a biologically active agent.
21. **(Previously Presented)** The method of claim 20 wherein said biologically active agent is selected from the group consisting of steroidal and non-steroidal antiinflammatories, fibrinolytics, hemostatics, antithrombotics, growth factors, antitumorals, antibacterials, antivirals and antifungals.
22. **(Previously Presented)** The method of claim 11 wherein the viscosity of said cross-linked derivative is at least $350 \text{ Pa}^* \text{ Sec}^{-1}$.
23. **(Previously Presented)** The method of claim 11 wherein the viscosity of said cross-linked derivative is at least $300 \text{ Pa}^* \text{ Sec}^{-1}$.
24. **(Original)** The method of claim 11 wherein said surgery is selected from the group consisting of abdominal, laparoscopic, laparotomic, intestinal, gynecologic, abdominalpelvic, peritoneal, urogenital, orthopedic, spinal/dura mater, tendon/nerve, including carpal tunnel,

cardiovascular, thoracic, ophtalmic, oncologic, plastic, esthetic, ENT, paranasal sinuses, and transplantation.

25. **(Previously Presented)** The method of claim 11, wherein the viscosity of said cross-linked derivative is at least $400 \text{ Pa}^* \text{ Sec}^{-1}$.

26. **(Currently Amended)** The method of claim 11, 27 or 29, wherein said auto-crosslinked derivative of an hyaluronic acid has an average molecular weight of 150,000 to 450,000 Daltons.

27. **(NEW)** A method for preventing surgical adhesions of tissue which comprises applying to tissue involved in surgery a biomaterial comprised of at least one auto-crosslinked derivative of an hyaluronic acid with an average molecular weight of 150,000 to 730,000 Daltons, wherein 4.5 to 5% of the carboxyl group of hyaluronic acid are cross-linked to the hydroxyl group of the same or different hyaluronic acid molecule.

28. **(NEW)** The method of claim 27, wherein said surgery is selected from the group consisting of abdominal, laparoscopic, laparotomic, intestinal, gynecologic, abdominalpelvic, peritoneal, urogenital, orthopedic, spinal/dura mater, tendon/nerve, including carpal tunnel, cardiovascular, thoracic, ophtalmic, oncologic, plastic, esthetic, ENT, paranasal sinuses, and transplantation.

29. **(NEW)** A method for preventing surgical adhesions of tissue which comprises applying to tissue involved in surgery a biomaterial comprised of at least one auto-crosslinked derivative

Application No. 10/812,587
Amendment dated March 12, 2008
Reply to Office Action of June 18, 2007

Docket No.: 2039-0124PUS2

of an hyaluronic acid, wherein 4.5 to 5% of the carboxyl group of hyaluronic acid are cross-linked to the hydroxyl group of the same or different hyaluronic acid molecule.

30. (NEW) The method according to claim 11, wherein said cross-linked derivative has a viscosity of $200 \text{ Pa} \cdot \text{sec}^{-1}$ to $450 \text{ Pa} \cdot \text{sec}^{-1}$.